Biomarkers in skin autoimmunity-An update on localised scleroderma

Area of Science:

• Immunology
• Dermatology
• Genetics

Background:

• Autoimmune diseases are diverse, impacting localized or systemic health.
• Localised scleroderma, affecting skin and subcutaneous tissue, lacks effective diagnostic and prognostic biomarkers.
• Understanding disease biology is crucial for developing clinical biomarkers.

Purpose of the Study:

• To review established and emerging biomarkers for localised scleroderma.
• To highlight recent genomic and epigenetic discoveries relevant to the disease.
• To explore potential improvements in diagnosis and treatment through biomarker research.

Main Methods:

• Literature review of established biomarkers (cell surface proteins, autoantibodies, cytokines).
• Analysis of recent genomic studies, including epigenetic regulation, RNA transcriptomics, and regulatory RNAs (microRNA, long non-coding RNA).
• Synthesis of findings to elucidate genetic mechanisms and clinical applications.

Main Results:

• Current biomarkers for localised scleroderma are limited for clinical differentiation and prognosis.
• Emerging biomarkers include epigenetic modifications, microRNAs, and long non-coding RNAs.
• Genomic studies are beginning to reveal underlying genetic mechanisms.

Conclusions:

• New genomic and epigenetic biomarkers show promise for localised scleroderma.
• These advancements could lead to improved diagnostic accuracy and prognostic capabilities.
• Further research is needed to translate these findings into effective clinical practice for autoimmune skin diseases.